藥明生物、信達生物及康方生物漲近6%-10%
本港最新失業率降至4.7%遠低預期。恆指今早隨歐美及區內股市造好,最高見21,098,現報21,039,回升378點或1.8%,成交額303億元。
藥業股今早以本月上旬訂立擬以每股24.27元向不少於六名承配合共配售2,400萬股的康方生物-B(09926.HK)表現最好,股價高見24.8元,現報24.6元,急彈9.8%,成交已達375萬股。
信達生物(01801.HK)公佈治療白血病藥「耐立克」上市申請正式獲國家藥監局已正式受理。該股扭三連跌,今早曾升逾7%高見37.95元,現報37.7元,回升6.5%,成交512萬股。
料中績多賺逾35%的藍籌藥明生物(02269.HK)獲高盛重申「買入」評級,以反映中績指引勝預期。該股三連升,最高見82.05元,現報81.95元,續升5.7%,暫爲最強藍籌。系內的藥明康德(02359.HK)高見106.6元,現報106.4元,回升4.2%。
康希諾(06185.HK)、神威藥業(02877.HK)及歌禮制藥-B(01672.HK)升近3%-4%,報73.9元、6.43元及3.58元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.